Exicure, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XCUR research report →
Range $12 – $12
Price Chart
About the company
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain.
- CEO
- Jungsoo Kim
- IPO
- 2018
- Employees
- 2
- HQ
- Redwood City, CA, US
Get TickerSpark's AI analysis on XCUR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.29M
- P/E
- -0.99
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 8.48
- EV/EBITDA
- -0.77
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -237.91%
- ROIC
- -93.88%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-460,000-192.0%
- Op Income
- $-10,117,000
- Net Income
- $-4,946,000+49.0%
- EPS
- $-0.79+50.3%
- OCF Growth
- -194.0%
- FCF Growth
- -194.0%
- 52W High
- $9.48
- 52W Low
- $1.18
- 50D MA
- $1.90
- 200D MA
- $3.72
- Beta
- 3.66
- RSI (14)
- 36
- Avg Volume
- 408.25K
No earnings-call transcripts are available for XCUR yet.
- Free Float
- 28.1%
- Shares Outstanding
- 6.37M
- Float Shares
- 1.79M
of shares held by institutions
15 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 42.04K | 0 |
Held by 18 ETFs
Biggest fund positions in XCUR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 8, 26 | Exicure HiTron Inc. | other | 117,441 |
| Jun 26, 26 | Exicure HiTron Inc. | other | 253,195 |
| Jun 24, 26 | Exicure HiTron Inc. | other | 123,456 |
| Jun 23, 26 | Exicure HiTron Inc. | other | 129,183 |
| Feb 16, 26 | Miller Josh | other | 8 |
| Jan 21, 26 | Exicure HiTron Inc. | sell | 258,367 |
| Jan 16, 26 | Exicure HiTron Inc. | sell | 734,747 |
| Jan 7, 26 | Exicure HiTron Inc. | sell | 741,272 |
| Dec 8, 25 | SANGSANGIN INVESTMENT & SECURITIES CO., LTD. | sell | 433,332 |
| Nov 16, 25 | Miller Josh | other | 7 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XCUR coverage
Recent articles, reports, and earnings notes.
No research on XCUR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XCUR report →Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
globenewswire.com · Aug 3
Exicure Announces Board and Committee Changes
globenewswire.com · Jun 30
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
globenewswire.com · Jun 10
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
globenewswire.com · Jun 10
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
globenewswire.com · Jun 1
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
globenewswire.com · Apr 22
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
globenewswire.com · Apr 22
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
globenewswire.com · Apr 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.